Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase

AIDS

Volumn 18, Issue 6, 2004, Pages 949-951

  Winston, Alan ^a   Pozniak, Anton ^a   Mandalia, Sundhiya ^a   Gazzard, Brian ^a   Pillay, Deenan ^b   Nelson, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; NUCLEOSIDE; NUCLEOTIDE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR;

ADD ON THERAPY; ARTICLE; CONTROLLED STUDY; DATA BASE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; TREATMENT FAILURE; VIROLOGY; VIRUS GENE; VIRUS ISOLATION; VIRUS RESISTANCE;

EID: 2142657848     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200404090-00014     Document Type: Article

References (6)

1. Gu Z, Arts EJ, Parniak MA, Wainberg MA. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2′,3′-dideoxycytidine 5′-triphosphate and other drugs. Proc Natl Acad Sci U S A 1995, 92:2760-2764.
2. Winston A, Mandalia S, Pillay D, Gazzard B, Pozniak A. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients. AIDS 2002, 16:2087-2089.
3. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, et al. In vitro selection and characterisation of HIV-1 with reduced susceptibility to PMPA. Antiviral Ther 1999, 4:87-94.
4. Margot NA, Issacson E, McGowan I, Cheng A, Miller MD. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J Acquired Immune Defic Syndr 2003, 33:15-21.
5. Miller MD, Margot NA, McColl DJ, Coakley DF, Cheng AK. Characteristics of virological failure through 96 weeks among treatment naïve patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz. In: 2nd International AIDS Society Conference. Paris, 2003 [Abstract 553].
6. Parikh U, Koontz D, Hammond J, Bacheler L, Schinazi R, Meyer P, et al. K65R: a multi-nucleoside resistance mutation of low but increasing frequency. Antiviral Ther 2003, 8 (Suppl.):S152.